Mission 2024
Genekam making ready for Nasdaq IPO 2024
Slide 1

LATEST NEWS:

Press is reporting a fatal infection in human being with avian influenza virus H5N2 in Mexico. Genekam has a kit for this pathogen available.

Ready to use real time PCR: Fluhunter avian influenza virus H5N2 FR356 100 reactions Euro 619.-

Slide 1

LATEST NEWS:

Genekam Biotechnology AG is developing diagnostic tests for early detection of SARS CoV-2 vaccine and post vaccination complications.

Slide 1

LATEST NEWS:

Genekam Biotechnology AG has developed a small molecule with potential to treat SARS CoV-2 vaccine complication and is going to start in vitro studies.

Slide 1

MEDICA 2024

Visit us on Medica Duesseldorf, 11.-14. November 2024

Slide 1

MICROBOSS Nanomedicine GmbH

(a spin-off of Genekam Biotechnology AG) is to attend the Bio Investor Forum in San Francisco, USA, from October 15–16, 2024, to present nanomedicine applications based on quantum dots magnetic beads conjugate applications to investors.

Slide 1

EUDAMED

A number of Genekam products are registered with EUDAMED
A step towards meeting the lastest IVDR requirements

Products

SHOWCASE

Latest Products

CONTACT US

Do You Have Any
Questions?

  • Genekam Biotechnology AG
    Duissern Str. 65a
    47058 Duisburg, Germany

  • 49 203 / 555 858 -31 / -32 / -33
    Mobil (WhatsApp): 49 (0)170 / 3503779
    Skype: genekam-biotechnology

  • anfrage@genekam.de